Table 2.
Evaluation results on AMSTAR2 scale.
| Included studies | Item 1 | Item 2* | Item 3 | Item 4* | Item 5 | Item 6 | Item 7* | Item 8 | Item 9* | Item 10 | Item 11* | Item 12 | Item 13* | Item 14 | Item 15* | Item 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Li (25) | Y | N | N | PY | Y | Y | N | PY | Y | N | Y | N | Y | N | N | N |
| Miaoxuan (26) | Y | N | N | PY | N | N | N | PY | Y | N | Y | N | N | Y | N | N |
| Hong-Na (27) | N | N | N | Y | Y | Y | N | PY | Y | N | Y | N | Y | Y | Y | N |
| Jing (28) | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | N | N | N | Y | N |
| Lihong (29) | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | N | N | N | N | N |
| Mohan (30) | N | N | N | PY | Y | Y | N | PY | Y | N | Y | N | Y | N | N | N |
| Sui (31) | Y | N | N | Y | N | Y | N | N | N | N | Y | N | Y | Y | Y | N |
| Yanhui (32) | Y | N | N | PY | Y | Y | N | N | Y | N | Y | Y | Y | N | N | N |
| Sha (33) | Y | N | N | PY | Y | Y | N | PY | Y | N | Y | N | Y | N | N | N |
| Wen (34) | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | N | Y | N | N | Y |
| Kwon (35) | Y | Y | N | PY | Y | Y | Y | PY | Y | N | Y | N | Y | N | Y | Y |
| Lam (36) | Y | N | N | Y | N | Y | N | PY | Y | N | NO Data consolidation | NO META | N | N | N | Y |
| Lee (37) | N | N | N | Y | N | Y | N | PY | Y | N | Y | N | Y | Y | N | Y |
| Lee (38) | Y | N | N | Y | Y | Y | N | Y | Y | N | Y | N | Y | Y | N | Y |
| Lee (39) | N | N | N | Y | N | Y | N | PY | Y | N | Y | N | N | Y | N | Y |
| Liu (40) | Y | N | N | PY | Y | Y | N | PY | Y | N | Y | N | Y | N | N | Y |
| Noh (41) | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | N | Y | Y | N | Y |
| Qiang (42) | Y | N | N | Y | Y | Y | N | Y | Y | N | Y | N | N | N | N | Y |
| Sun (44) | Y | N | N | PY | Y | Y | N | PY | Y | N | Y | N | N | N | N | N |
| Fu (43) | Y | N | N | PY | Y | Y | N | PY | Y | N | Y | N | N | N | Y | N |
| Pereira (45) | Y | N | N | Y | Y | Y | N | PY | N | N | NO Data consolidation | NO META | N | N | N | Y |
| Li (46) | Y | N | N | PY | Y | Y | N | PY | Y | N | Y | N | Y | N | Y | Y |
| Wei (47) | N | N | N | PY | Y | Y | N | PY | Y | N | Y | N | N | N | N | Y |
*, Key item; Y, Yes; N, No; PY, Partially yes; Item 1: do the study questions and inclusion criteria include PICO? Item 2: Are there pre-published plans? Is there a clear bias between research and programmes? Item 3: Did the author explain the type of study design included? Item 4: Are comprehensive literature retrieval strategies used? Item 5: Were repeated studies screened? Item 6: Do you perform repeated data extraction? Item 7: Do you provide a list of excluded documents and explain why? Item 8: Are the included studies described in detail? Item 9: Were reasonable tools used to assess the risk of bias for each included study? Item 10: Are the funding sources included in the study reported? Item 11: If a meta-analysis is performed, are the results statistically combined using appropriate methods? Item 12: If a meta-analysis is performed, is the impact of bias risk explained in the results? Item 13: If a meta-analysis was performed, is the discussion explaining the effect of the risk of bias? Item 14: Is there a reasonable explanation for heterogeneity in the discussion? Item 15: If quantitative analysis is performed, are publication biases sufficiently investigated and their possible impacts discussed? Item 16: Are there any potential sources of conflicts of interest reported?